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Abstract 
Background and Purpose: The Clavien-Dindo- Grade (CDG) is a therapy-oriented 
grading system that classifies complications in response to necessary therapy in five 
grades (CDG 1= lowest grade, CDG 5= highest grade). The aim of this study is to 
validate CDG in a defined neurosurgical patient population with extracranial carotid 
artery stenosis who underwent carotid endarterectomy (CEA). 
Methods: Patients were retrieved from a prospectively-collected database of patients 
who underwent CEA at the Department of Neurosurgery, University Hospital Zurich 
between January 2015 and March 2018. Complications at discharge and short-term 
follow-up (3 months after surgery) were rated by CDG. Patients’ outcomes and 
neurological status were graded with the modified Rankin Scale (mRS) and National 
Institute of Health Stroke Scale (NIHSS). 
Results: 119 patients underwent surgeries for a total of 120 CEAs (one patient 
received both-side CEA). 108 patients received treatment for symptomatic carotid 
artery stenosis. At discharge, ten (8.4%) patients showed some deviation from the 
normal post-operative course (CDG ≥ 1), with a median CDG of 2. Three (2.5%) of 
these complications were additionally graded with a “d” indicating new neurological 
deficits. None of the patients treated for asymptomatic carotid artery stenosis (n=11) 
presented any deviation from the normal post-operative course (CDG ≥ 1). Patients 
with higher CDG had significantly higher NIHSS (p=0.001; R2 =1) and significantly 
higher mRS (p= 0.001; R2 =1). The complication group was associated with a longer 
stay in hospital (p<0.0001). 
 
Conclusion: Our study has demonstrated the correlation between clinically-relevant 
outcome scales (mRS and NIHSS) and the length of hospital stay with CDG in a well-
defined neurosurgical patient population. These results show that CDG is a valid 
instrument for classifying early complications after CEA.  
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1. List of abbreviations 
CAS Carotid artery stenting  
CCI Comprehensive complication index 
CDG Clavien-Dindo-Grade 
CEA Carotid endarterectomy 
CTA Computed tomography angiography 
DUS Duplex ultrasound 
ICA Internal carotid artery 
KISIM Klinikinformationssystem 
MCA Middle cerebral artery 
MR Magnetic resonance 
MRA Magnetic resonance angiography 
mRS Modified Rankin Scale 
NASCET North American Symptomatic Carotid Endarterectomy Trial 
NIHSS National Institute of Health Stroke Scale  




Carotid endarterectomy (CEA) is an effective surgical procedure to reduce the risk of 
ischemic stroke in patients with high-grade extracranial carotid artery stenosis.1 
2.1. Definitions and etiology 
Ischemic stroke is the second most common cause of death in Europe and the most 
common reason for acquired disability.2 Ischemic stroke is defined as a focal, 
occasionally global, loss of neurological function over 24 hours with underlying 
vascular etiology. Similar events lasting under 24 hours are called a transient ischemic 
attack (TIA).  
The main cause of carotid disease is a result of atherosclerosis with the deposition of 
cholesterol and fibrotic tissue in the arterial wall due to genetic and lifestyle factors. In 
Caucasians, it is mostly found in the extracranial carotid bifurcation.2 
 
Extracranial atherosclerotic disease accounts for up to 15-20% of all ischemic 
strokes.3,4 A clear correlation between the degree of stenosis and the risk of stroke 
was documented in the North American Symptomatic Carotid Endarterectomy Trial 
(NASCET).5 
 
2.2. Measurement of stenosis severity 
Conventional digital subtraction angiography (DSA) is the gold standard for evaluating 
the true severity of internal carotid artery stenosis.  
However, non-invasive tests – carotid duplex ultrasound (DUS), magnetic resonance 
angiography (MRA), and computed tomographic angiography (CTA) – are preferred in 
current clinical practice because DSA is an invasive procedure associated with a 
possible risk of stroke and other complications.6 
NASCET criteria uses the normal distal ICA as a denominator and are based on DSA. 
Nowadays, the degree of stenosis is rather estimated measuring velocity of the flow 




Medical advances in recent years along with aggressive cardiovascular risk factor 
modifications have resulted in reduced recurrence rates of atherosclerotic stroke. 
Recent medical breakthroughs in the primary and secondary prevention of 
atherosclerotic stroke through lifestyle modifications and novel treatment of modifiable 
risk factors for atherosclerosis play a crucial role in the treatment of affected patients.8 
Primary prevention is made by avoiding the development of a carotid disease through 
lifestyle modification, as recommended by the American Heart Association (AHA) 
guidelines.9 
Secondary prevention focuses on reducing the clinical impact in patients with 
asymptomatic diseases. 10-15% first-ever stroke patients have had a previously-
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untreated asymptomatic carotid artery stenosis.7 Moderate stenosis in asymptomatic 
patients over 65 years can be found in about 2% of the population.7  
Tertiary prevention is made to reduce recurrent stroke due to carotid stenosis in 
symptomatic patients. A carotid artery stenosis is defined as symptomatic if symptoms 
presented within the preceding 6 months. Symptoms might be hemi-sensory 
impairment, hemi-motor deficits and higher cortical dysfunction, mostly appearing as a 
loss of function.  
Risk factors for plaque progression are smoking, high blood pressure, obesity, male 
sex and age over 65 years.7 
Therapy 
The goal of primary and secondary prevention is to reduce the risk factors through 
adapting one’s lifestyle. Medical prevention in both types is achieved with lipid-lowering 
medication, management of hypertension with blood pressure goals <140/90mmHg 
and strict glycemic control in diabetic patients.7  
Antiplatelet therapy with aspirin (75 or 325 mg daily) is recommended for patients with 
obstructive or non-obstructive atherosclerosis for preventing ischemic events, although 
the benefit has not been established for preventing stroke in asymptomatic patients. In 
patients with extracranial carotid disease who have sustained ischemic stroke or TIA, 
antiplatelet therapy alone or the combination with dipyridamole is recommended.7,10 
The guidelines recommend that patients with >50% stenosis without intervention 
should be treated with ASS or Clopidogrel as part of the best medical therapy. Early 
Clopidogrel and ASS before CEA in symptomatic patients with >70% stenosis seem to 
reduce recurrent events. 7 
Tertiary prevention represents the treatment (surgical or endovascular) of symptomatic 
high-grade extracranial carotid stenosis. CEA is established as safe and effective by 
randomized controlled trials for reducing the risk of ischemic stroke in both 
symptomatic and asymptomatic patients with carotid artery atherosclerosis. Carotid 




CEA comprises 1) exposing the carotid artery through a small neck incision, and 2) 
opening the carotid artery and removing the atherosclerotic plaque from the vessel 
wall. The goal of such a procedure is stroke prevention. It is a durable procedure but 
not a cure: although rare, the accumulation of atherosclerotic material can occur 
again.7 
Indication and timing in symptomatic patients 
CEA is recommended in patients reporting carotid territory symptoms within the 
preceding 6 months and who have a 70-99% carotid stenosis, provided that the 
documented procedural death/stroke rate is <6% (Class I – Level A). CEA should be 
considered in patients reporting carotid territory symptoms within the preceding 6 
months and who have a 50-69% carotid stenosis, provided that the documented 
procedural death/stroke rate is <6% (Class IIa – Level A).7 In patients with <50% 
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stenosis CEA can be considered if symptoms are recurring despite the best medical 
therapy.7  
The maximum benefit is seen if CEA is performed within 14 days after the onset of 
symptoms.11 Urgent CEA is defined as surgery within 48 hours of the clinical onset of 
symptoms: it is rarely performed and should be considered in situations such as 
crescendo TIAs or stroke in progress, or fluctuating thrombus. 
It is recommended that most patients who have suffered carotid territory symptoms 
within the preceding 6 months, are aged >70 years and have 50-99% stenosis should 
be treated by CEA rather than CAS (Class I – Level A). 
Indication in asymptomatic patients 
In “average surgical risk” patients with an asymptomatic 60-99% stenosis, CEA should 
be considered in the presence of one or more imaging characteristics that may be 
associated with an increased risk of late ipsilateral stroke, provided that the 
documented perioperative stroke/death rates are <3% and the patient’s life expectancy 
exceeds 5 years (class IIA - Level B). Imaging/clinical criteria that might confer an 
increased risk of stroke on best medical treatment include silent infarction on 
neuroimaging, stenosis progression, large plaque area, ultrasound plaque 
characteristics such as plaque echolucency, intra-plaque hemorrhage on MRI, 
impaired cerebrovascular reserve, spontaneous embolization on trans-cranial Doppler 
ultrasound, and a history of contralateral TIA.7 
High-risk patients for CEA 
Anatomical or clinical factors significantly increasing the risk of complications after CEA 
are significant cardiac or pulmonary disease, contralateral laryngeal-nerve palsy, 
previous radical neck surgery, cervical radiation therapy, and recurrent stenosis after 
CEA.7 
In these high-risk patients for CEA, CAS should be evaluated. If CAS is considered 
risky, best medical therapy alone with lifestyle adaptation should be considered as an 
option. 7  
Complications after CEA 
Complications occurring immediately after CEA include intraoperative stroke with 
persisting neurological deficit and/or post-operative stroke. Furthermore, 
hemodynamic instability such as hypotension or more often hypertension can be 
seen.12 Cranial nerve injuries such as recurrent laryngeal, hypoglossal or facial nerve 
palsy might appear immediately, although very few persist after one month.2  
New post-operative ischemic lesions following CEA show an incidence between 8.8% 
and 12.2%.2,13 
Classification of complications 
 
In order to improve patients’ outcome, it holds importance to report and analyze 
surgery-related complications completely and objectively, mostly in a prospective 
fashion. The Clavien-Dindo-Grade (CDG) is a therapy-oriented grading system 
developed to classify surgical complications depending on the type of treatment 
required for a given complication. CDG rates any deviation from the normal and 
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expected post-surgical course in five grades. CDG was initially developed for visceral 
surgery.14 Thereafter, it also proved to be a useful tool to rate complications in other 
surgical specialties, such as orthopedics, urology, gynecology,15-17 and 
neurosurgery.18,19  
CDG grade can either remain stable or worsen (increase) over time: in fact, any new 
complication occurring during the post-operative course will be considered and then 
graded. Therefore, CDG cannot improve (decrease) over time. This is in contrast to 
the outcome scales, which can both improve and worsen over time, depending on 
patients’ clinical condition.  
 
2.5. Study objective 
The aim of this study is to test the applicability of CDG in a well-defined neurosurgical 





A retrospective study was performed using a prospectively-collected database of a 
well-defined cohort. 
3.1. Setting and patients selection 
Patients were retrieved from a prospectively-collected database of subjects who 
received CEA at the Neurosurgical Department of University Hospital between January 
2015 and March 2018. The indication and type of treatment (CEA vs. CAS) of patients 
with carotid stenosis is discussed at the weekly multidisciplinary cerebrovascular 
board. All patients underwent a preoperative DUS examination as well as CTA and/or 
MRA.  
Post-operative follow-up protocol includes routine clinical and radiological (by means 
of MRA or CTA) examination prior to discharge, as well as a short-term follow-up at 3 
months after surgery including DUS. 
 
3.2. Evaluation of the patient outcome 
National Institute of Health Stroke Scale (NIHSS) 
NIHSS quantifies neurological deficits after stroke (Table 2). The NIHSS comprises 
eleven items, each of which scores a specific ability between 0 and 4. A score of 0 
indicates normal function in that specific ability, while a higher score is indicative of 
some level of impairment. The individual scores from each item are summed to 
calculate a patient's total NIHSS score. The maximum possible score is 42, while the 
minimum score is 0.20 
 
Modified Rankin Scale (mRS) 
mRS is a disability scale that is applied to measure the grade of disability after a stroke. 
The scale runs from 0 (no symptoms) to 6 (death). The modified Rankin Scale (mRS) 
is the most widely-used outcome measure in stroke clinical trials (Table 3).21 
 
3.3. Complications graded by Clavien-Dindo grading system 
CDG is a complication scale that registers any deviation of the normal post-operative 
course and classifies these deviations (complications) in five grades (from grade 1 to 
grade 5) based on the therapeutic consequences (Table 4, Figure 1).3,4 CDG grade 1 
contains any deviation from the normal post-operative course without the need for any 
intervention. CDG grade 2 complications require pharmacological treatment and CDG 
grade 3 complications require an intervention: for an intervention without general 
anesthesia, the complications is registered with CDG grade 3a and for intervention 
under general anesthesia with CDG grade 3b. CDG grade 4 registers patients with a 
life-threatening complication and need for an ICU stay (the complication is registered 
with CDG grade 4a if a single-organ dysfunction is present and CDG grade 4b in case 
of multi-organ dysfunction). The death of patients within 30 days is graded with CDG 
5.3,4 Moreover, in this study we introduce “d” as an additional marker for new 
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neurological deficits after CEA.  
3.4. Statistical analysis 
All statistical analysis were performed with GraphPad Prism 8 
(https://www.graphpad.com/). T-tests, Fisher’s exact test and Chi-square with Yates’ 
correction were used for hypothesis testing. Significance was accepted at a p-value 
<0.05. The association between CDG and performance (mRS, NIHSS) or length of 
hospital stay was assessed using Spearman’s rank correlation and presented with rho 
effect sizes and p-values. Rho was interpreted as follows: 0.0 ≤ rho ≤ 0.2 shows no to 
very slight correlation, 0.2 ≤ rho ≤ 0.5 shows slight to moderate correlation, 0.5 ≤ rho ≤ 
0.8 shows clear correlation and 0.8 ≤ rho ≤ 1.0 shows high up to perfect correlation.  
 
3.5. Ethics 
Patient data and outcomes were prospectively collected in an institutional patient 
registry, which was approved upfront by the local ethics review board (Kantonale 
Ethikkommission PB-2017-00093) and internationally registered at clinicaltrials.gov 
(NCT01628406). Patient consent was waived due to the observational nature of the 
study. The scientific workup was approved upfront by the local ethics review board 
(Kantonale Ethikkommission KEK-ZH 2012-0244). 





119 patients underwent a total of 120 CEAs (one patient received both-side CEA). 108 
patients received treatment for symptomatic carotid artery disease.  
4.1. Complications at discharge 
At discharge, ten (8.4%) patients showed some deviation of the normal post-operative 
course (CDG ≥ 1), with a median CDG 2 (min. CDG 1 and max. CDG 5).  
Three (2.5%) of these complications were additionally graded with a “d” indicating new 
neurological deficits. None of the patients treated for asymptomatic carotid artery 
diseases (n=11) presented any deviation of the normal post-operative course. 
Patients with higher CDG had significantly higher NIHSS (p=0,001, R2 =1) and 
significant higher mRS (p= 0,001, R2 =1) at discharge. 
By categorizing the patient population into a non-complication group (CDG 0) and a 
complication group (CDG ≥ 1), NIHSS significantly increased in the complication group 
(0(1) vs. 23(42), p< 0.0001) as well as mRS (1(1) vs. 5(6), p<0.0001). 
 
4.2. Impact of complications on hospital stay 
Patients stayed in hospital for 6.0 ± 4.2 days on average. The median stay in hospital 
was 5 days (range: 0 - 23 days). Any deviation from the normal post-operative course 
(CDG ≥ 1) was associated with a longer stay in hospital (11.9 ± 5.3 days vs. 5.7 ± 3.9 
days, p-value < 0.0001). No statistical difference was seen in the length of hospital 
stay between patients with new neurological deficits (“d”) and those without “d” (10 ± 
2.7 days vs. 12.7 ± 6.1 days; p= 0.49).  
 
4.3. Complications at short-term follow-up (3 months) 
At short-term follow-up (3 months), no new deviation of the normal post-operative 
course (CDG ≥ 1) was recorded. 
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5. Discussion 
With the prospective use of the CDG system, we analyzed the well-defined patient 
population with carotid artery stenosis who underwent CEA. We showed a clear, 
statistically significant correlation between CDG and outcome grading systems (NIHSS 
and mRS) at discharge. Moreover, a significant correlation between CDG and patients’ 
hospital stay was seen.  
This study promotes CDG as an applicable grading system for complications after 
CEA.  
 
5.1. Complications rates and comparison to literature 
In our cohort, any deviation from normal post-operative course (CDG ≥1) at discharge 
was recorded in ten patients (8.3%), with a median of CDG 2. Three (2.5%) of these 
complications were additionally graded with a “d”, thus indicating new neurological 
deficits.  
Reported reasons of re-admission by others lie at 6.5% and comprise hemorrhage, 
vascular or graft complications, neurologic deficits, venous thromboembolism as well 
as perioperative complications such as cardiac, respiratory, urologic, renal, infectious 
and gastrointestinal incidents.7  
In our cohort, one patient (0.8%) presented at discharge with persistent but 
asymptomatic stenosis. No symptomatic re-occlusion was registered at discharge and 
no symptomatic re-stenosis or re-occlusion was seen at short-term follow-up. DUS 
showed one (0.8%) new asymptomatic mild (10-40%) re-stenosis at 3 months follow-
up. Brott10 reported an overall rate of hemodynamically-significant re-stenosis in 5-7% 
after one year of follow-up. 
The risk for cranial nerve injuries is 8.6%, according to NASCET.22 In our cohort, two 
patients (1.7%) suffered from cranial nerve injury at discharge. At short-term follow-up, 
one of the patients had completely recovered, whereas the other had clearly improved.  
In our cohort, one (0.8%) symptomatic stroke was seen at discharge. Literature reports 
an overall stroke rate of 7%.22 One patient died, which expresses a mortality rate of 
0.8% in our cohort. In literature23, the overall death rate within 30 days was 3.1%. 
 
5.2. Advantages and disadvantages of CDG 
CDG provides a simple, reproducible, objective, and applicable therapy-oriented way 
of classifying post-surgical complications, which was precisely the aim of Clavien et 
al.14 There is no subjective component, such as “minor” or “major” complications, and 
the grading system enables a comparison between case series in different institutions. 
The CDG score has been widely used in other surgical disciplines such as visceral or 
orthopedic surgery15,16,24 and thus it facilitates comparisons between surgical 
specialties.18 Furthermore, there is no underreporting of complications due to the 
registration of any deviation from the normal post-surgical procedure as a definition of 
the CDG grading system. 
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Several studies have shown that CDG is clinically relevant and associated with 
patients’ outcome and the length of hospital stay in spine, orthopedic, and visceral 
surgery.16,18,25-27 Nevertheless, it is not obvious that CDG can be used for cranial 
surgery where complications can cause severe neurological deficits. Some of the 
neurological complications do not demand sophisticated invasive treatments and are 
therefore graded low in CDG, although they may be associated with worse patient 
outcomes. The same concern was discussed by Bellut et al.18 for patients undergoing 
lumbar spine surgery. 
In the CDG classification of 2009,14 the suffix “d” – which can be added to any CDG 
class – was used to indicate a persistent (disabling) complication at the time of 
discharge or follow-up that compromises health condition and is directly related to the 
treatment. Based on our experience with the use of CDG in neurosurgery,28 18,19 we 
use the suffix “d” to indicate a new neurologic deficit after a neurosurgical procedure 
that is present at the time of discharge or follow-up.  
 
5.3. Modifications of CDG grading system 
Landriel-Ibañez et al.29 developed a modified CDG score for cranial and spine 
procedures. As in CDG, the categories used to grade complications are based on the 
therapy used to treat the complications but labeled as follows: I (mild), II (moderate), 
III (severe), and IV (death). This score was presented as a simple and easily 
reproducible way to report negative outcomes based on the therapy administered to 
treat a complication.29  
Schiavolin et al.30 used the same Landriel-Ibañez classification system in 1,008 
patients who underwent elective neurosurgical procedures. 14.3% of the patients had 
cerebrovascular diseases (e.g. aneurysm, cavernous hemangioma, arteriovenous 
malformations, and ischemic cerebral disease requiring bypass procedure). No su-
division of complications into the respective cerebrovascular disease group was 
performed; therefore, no comparison with our CEA cohort is possible. However, 
strong correlation with the Karnofsky performance scale was found.  
 
5.4. Limitations 
We arbitrarily decided to limit the follow-up analysis and CDG validation to 3 months. 
For patients who undergo CEA, this is the standard interval for post-operative routine 
visits, according to our protocol. Moreover, other published complication studies in 
neurosurgery also limited the follow-up time period similar to the one that we used.18,29 
Second, all analyses were carried out on data from a single reference center. 
Therefore, the study population is small due to a very selected cohort of patients who 
underwent CEA. Thus, we cannot generalize our results to other populations and 
centers with different decision protocols. We did not perform sub-group analysis or 
multivariate analysis for patients at high medical risk, which could have an impact on 
the incidence of complications due to the small study group. An external validation or 




CDG is an applicable grading system for classifying complications after CEA. A 
significant correlation between the CDG system and outcome scales (mRS and 
NIHSS) as well as between CDG and the length of hospital stay was documented. 
Moreover, in this study “d” was introduced as an additional marker for new neurological 
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7. Tables and Figures 

































Male (%) / Female (%) 77 (65%) / 42(35%) 
Mean age (range) 73 (45-95) 
Cardiovascular risk factors: 
• Diabetes mellitus 







Mean (±standard deviation)  
hospital stay 
6.0 ± 4.2 days 
Median hospital stay  5 days (range: 0 - 23 days)  
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Table 3. Modified Rankin Scale (mRS) 
 
0: no symptoms at all 
1: no significant disability despite symptoms; able to carry out all usual 
duties and activities 
2: slight disability; unable to carry out all previous activities, but able to 
look after own affairs without assistance 
3: moderate disability; requiring some help, but able to walk without 
assistance 
4: moderately severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5: severe disability; bedridden, incontinent and requiring constant nursing 
care and attention 
6: death of the patient 
 
Table 2. Clavien-Dindo - Grading system (CDG), persistent neurological deficits and 










Number of patients 
with complications  





 No complications 109 (91.6%)  
1 any deviation from normal post-
operative course 
2 (1.7%) 2 (100%) 
2 requiring pharmacological 
treatment 
4 (3,4%) 0 (0%) 
3a requiring surgical intervention 
without general anesthesia 
1 (0.8%) 0 (0%) 
3b requiring surgical intervention 
with general anesthesia 
2 (1.7%) 1 (50%) 
4a life-threatening complication, 
ICU, single-organ dysfunction 
0 (0%) 0 (0%) 
4b life-threatening complication, 
ICU, multi-organ dysfunction 
0 (0%) 0 (0%) 




Figure 1. Distribution of patients with (CDG ≥1) and without complications at discharge 































a)  b)  
 
Figure 2. Correlation between complications occurring at discharge and patients’ 
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